



ASX ANNOUNCEMENT

Actinogen completes global patent family grant

Key Highlights:

- Final country (Brazil) patent granted for “Webster 7” family, which completes global grant process for this composition of matter patent family
- The Xanamem molecule is now patent protected across all key pharmaceutical markets to cover any use in all diseases, including Alzheimer’s Disease (AD) and other neurological diseases
- Composition of matter patent for Xanamem in most key markets can be extended to up to 2036

Sydney, 23 August 2021. Actinogen Medical (ASX: ACW, ‘ACW’ or ‘the Company’) is pleased to announce that it has received official notification from the Brazilian Patent and Trademark Office of grant of its patent application for Xanamem. The grant of the Brazilian patent completes a key part of Actinogen’s intellectual property (IP) portfolio, with protection across all major pharmaceutical markets including the USA, UK, EU, Japan, China, Canada and Australia. The patents provide exclusive rights in these regions and cover the composition of matter of Xanamem and its use in all diseases including AD and Fragile X Syndrome.

Globally, this patent encompasses composition of matter protection to 2031 with the possibility to extend by an additional 5 years in markets including Australia, the US, the EU, Korea, Japan, China, and Israel.

Last year Actinogen filed additional patents designed to further extend patent protection for Xanamem and continues to follow other strategies to strengthen its intellectual property position, such as paediatric development programs and orphan designations.

Dr Steven Gourlay, Actinogen CEO and MD commented:

“The addition of the Brazilian patent marks the completion of Xanamem’s composition of matter IP portfolio in all major markets. We expect that patent extensions, additional patents and regulatory mechanisms such as orphan designation will further extend its intellectual property protection.”

ENDS

Actinogen Medical

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E: steven.gourlay@actinogen.com.au

Investors

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

ACTINOGEN MEDICAL LIMITED TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 AUSTRALIA
TELEPHONE +61 2 8964 7401
WEB www.actinogen.com.au

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological diseases associated with dysregulated brain cortisol. The company is currently developing its lead compound, Xanamem™, as a promising new therapy for Alzheimer's Disease, Fragile X syndrome, and other potential neurological diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and behaviour and neuropsychological symptoms.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 200 volunteers and patients, finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase II studies in multiple indications will be conducted to further confirm and characterise Xanamem's efficacy and safety.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem™ is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.